WillItSurvive
Pharma and healthcare groups · United States

Neurocrine Biosciences

neurocrine.com ↗

Biopharma selling INGREZZA for tardive dyskinesia, now expanding into rare disease and endocrinology.

Hard to displace
Assessed 24 July 2026 · Evidence as of 24 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 24 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: Phase 3 readouts for osavampator (depression/bipolar) and direclidine (schizophrenia)
The call

Neurocrine runs on patent-protected revenue from INGREZZA and a growing rare-disease line, with Teva as a coexisting rival rather than a company taking its business away.

Neurocrine makes FDA-approved medications for movement disorders and other brain conditions, with two main drugs locked in by patents until the late 2030s and early 2040s. Competitors like Teva have similar drugs in the same small market, so Neurocrine is not a solo player, but its legal patent protection makes it very hard for generics or copies to take market share in the near term. The big risk is that one drug supplies 85 percent of revenue, so a failed clinical trial or pricing pressure from the government in 2029 could hurt, though the company is trying to reduce this risk by buying other smaller drug programs.

Why
01
AI pressure: None apparent. AI speeds up drug discovery industry-wide but has not touched Neurocrine's approved, patent-protected products yet. Could AI do the core job? Unlikely.
02
Bigger players: Teva Pharmaceutical Industries (AUSTEDO XR). Teva's AUSTEDO XR competes head to head in tardive dyskinesia, splitting the market roughly evenly with INGREZZA rather than displacing it. Could a giant copy it? No, they are blocked.
03
What protects it. Patents on INGREZZA to 2038 and CRENESSITY into the early 2040s, plus a specialized commercial sales force and FDA approval barriers.
What would change this call
Teva reports AUSTEDO XR revenue growth or share gains in quarterly filings through 2027. Would show Teva actively pulling tardive dyskinesia patients away from INGREZZA.
Neurocrine's INGREZZA revenue growth rate versus 2026 guidance of $2.7-2.8B in coming quarterly reports. Slower-than-guided growth could indicate share loss to Teva or new entrants.
Phase 3 readouts for osavampator and direclidine expected within the next year. Failures would remove pipeline diversification, increasing reliance on INGREZZA amid Teva competition.
Key numbers
  • Full-year 2025 net product sales $2.83B, up 22% YoY (2025-12-31)
  • INGREZZA 2025 revenue $2.51B, up 9% YoY (2025-12-31)
  • Q1 2026 net product sales $811.0M, up 44% YoY (2026-03-31)
Named risks
  • INGREZZA concentration, roughly 85 to 89 percent of 2025 net product sales. Severity: high
  • IRA Medicare price negotiation applicability beginning 2029 after INGREZZA's exemption through 2027 selection. Severity: medium
  • Phase 3 pipeline binary readouts for osavampator and direclidine could miss, compressing valuation. Severity: medium
  • Teva's AUSTEDO XR could gain share in the tardive dyskinesia duopoly. Severity: low
  • Soleno integration and VYKAT XR scale-up could produce cost or execution surprises post May 2026 close. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Teva Pharmaceutical IndustriescontestingNeurocrine and Teva held ~85% combined tardive dyskinesia share, ~$3.9B, in 2024; ongoing head-to-head data war through Apr 2026
Nxera PharmacontestingPartner on direclidine and NBI-1117570 but also an independent CNS/GPCR drug discovery competitor
Novo Nordisklosing toNovo Nordisk partnered with OpenAI for AI-driven drug discovery in April 2026; Neurocrine has no reported equivalent frontier-AI deal
Acadia PharmaceuticalscontestingNamed as another CNS/tardive dyskinesia market player alongside Neurocrine
Questions people ask
Is Neurocrine Biosciences profitable in 2026?
Yes. Neurocrine reported Q1 2026 net product sales of $811.0 million, up 44% year over year, with non-GAAP EPS of $1.94 beating estimates, as of March 31, 2026. Full-year 2025 net product sales were $2.83 billion, up 22% from 2024, showing sustained profitable growth.
Could AI replace Neurocrine Biosciences?
Unlikely soon. Neurocrine's revenue comes from FDA-approved, patent-protected drugs, INGREZZA protected to 2038 and CRENESSITY into the early 2040s, plus a roughly 600-person specialized sales force. AI affects early drug discovery, which Neurocrine largely outsources via licensing and M&A, not its approved commercial products.
Who is Neurocrine Biosciences' biggest competitor?
Teva Pharmaceutical Industries, via its drug AUSTEDO XR, is Neurocrine's main rival in tardive dyskinesia. As of 2024, Neurocrine and Teva together held roughly 85% combined market share in that indication, worth about $3.9 billion combined, per a January 2026 market report.
Does Neurocrine Biosciences rely too heavily on one drug, INGREZZA?
INGREZZA drove $2.51 billion of Neurocrine's $2.83 billion in full-year 2025 net product sales, making it roughly 85% to 89% of revenue. The company is diversifying via CRENESSITY ($301.2M in 2025) and the $2.9 billion Soleno acquisition closed May 18, 2026, adding VYKAT XR.
What did Neurocrine Biosciences acquire in 2026?
Neurocrine completed a $2.9 billion cash tender offer acquisition of Soleno Therapeutics at $53.00 per share, closing May 18, 2026, after announcing the deal April 6, 2026. Soleno makes VYKAT XR for Prader-Willi syndrome, which generated $190 million in 2025, its first launch year.
Who owns Neurocrine Biosciences?
Neurocrine Biosciences is an independent, publicly traded company on Nasdaq under ticker NBIX, not owned by any parent company. Its market capitalization was approximately $17.4 billion as of July 23, 2026, with shares trading near $174.
Timeline
  • 2026-07-23Announces senior leadership hires and promotions; market cap ~$17.4B, shares ~$174
  • 2026-05-18Completes $2.9B acquisition of Soleno Therapeutics at $53.00/share
  • 2026-05-05Reports Q1 2026 net product sales of $811.0M, up 44% YoY
  • 2026-04-13Doses first patient in Phase 2 trial of NBI-1117570 for schizophrenia, triggers $22.5M milestone
  • 2026-04-06Announces deal to acquire Soleno Therapeutics for $2.9B
  • 2026-02-11Reports full-year 2025 net product sales of $2.83B, up 22% YoY
  • 2026-01-16Presents head-to-head INGREZZA data vs Teva's AUSTEDO XR
  • 2026-01-08Announces $65M divestiture of European rare-disease unit to Immedica Pharma
  • 2025-11-03Signs up to $881.5M licensing deal with TransThera Sciences for NLRP3 inhibitors
  • 2024-12CRENESSITY approved for classic congenital adrenal hyperplasia
Revision history
24 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources